ABBOTT

Corporate Regulatory and Quality Science

Zena Kaufman
Director
Quality Center of Excellence
D-03QA, AP6C-1
Telephone: (847) 938-1750

100 Abbott Park Road
Abbott Park, IL 60064-6091
Facsimile: (847) 938-4422
e-mail: zena.kaufman@abbott.com

July 13, 2006

Division of Dockets Management (HFA-305)
Food and Drug Administration
5630 Fishers Lane
Room 1061
Rockville, MD 20857

Ref: Docket Nos. 1992N-0297 (Formerly 92N-0297), 1988N-0258 (Formerly 88N-0258), 2006D-0226 - Compliance Policy Guide 160.900: Prescription Drug Marketing Act Pedigree Requirements Under 21 CFR Part 203

To Whom it May Concern:

Abbott is very pleased to have the opportunity to provide comments on the Draft Compliance Policy Guide 160.900: Prescription Drug Marketing Act Pedigree Requirements Under 21 CFR Part 203 published on June 14, 2006 in the Federal Register.

Comments:
Abbott agrees with the content of the draft Compliance Policy Guide as well as agrees there is merit in providing a list of drug products that have been counterfeited in the past. To ensure the list of products remains current, we encourage the CPG expire after one year of publication as suggested in the draft. In one year, the document content, including the list of examples, can be reviewed and revised as appropriate.

We thank the Food and Drug Administration for your consideration of our comments. Should you have any questions, please contact Kathy Wessberg (tel: 847-938-1264, e-mail: kathy.wessberg@abbott.com).

Sincerely,

Zena Kaufman